MegaGen Terminates Straumann Option

Posted: March 1, 2017
Edited by Dentaltown staff

ENGLEWOOD CLIFFS, N.J.—Dental implant company MegaGen has announced the termination of the Straumann Group convertible bond and returned the $30 million plus interest that was earmarked for conversion into MegaGen shares.

The terms of the conversion and its associated valuation were in dispute and MegaGen agreed to terminate the investment and continue as an independent private company.

As the exclusive North American partner of MegaGen, ids has become one of the largest sellers of MegaGen products in three years. Ids is supportive of the termination and believes that remaining independent will allow ids and MegaGen to remain fast to innovate and follow their strategy of quality, unique user benefits and distribution through traditional dental dealers.

This agreement will ensure that the existing MegaGen global distribution network will expand. Additionally, MegaGen’s new $80 million factory is set to open in August 2017 and will provide additional capacity to manufacture a broad range of products. Currently the R2Gate Treatment Planning and Surgical Guide software is being launched worldwide.

During the upcoming IDS Show in Koln, Germany MegaGen and ids will display a large portfolio of new products in Hall 4.2 Stand N060.
Views: 719
Sponsors
Townie Perks
Townie® Poll
Do you do more or less endo procedures since you started practicing?
  
The Dentaltown Team, Farran Media Support
Phone: +1-480-445-9710
Email: support@dentaltown.com
©2025 Dentaltown, a division of Farran Media • All Rights Reserved
9633 S. 48th Street Suite 200 • Phoenix, AZ 85044 • Phone:+1-480-598-0001 • Fax:+1-480-598-3450